In this publication, we reported that many patients with AERD have ear/hearing-related symptoms that are…
Dupilumab Treatment for Aspirin-Exacerbated Respiratory Disease in a Real-World Setting: Impact on Quality of Life and Healthcare Utilization
We completed a 24-month long, survey-based study examining the health care utilization and symptom burden in patients with AERD. We found that at the end of 24 months, the participants who were on dupilumab at the start of the 2-year study and those that started dupilumab during the 2-year study period, had fewer poor health days and improved asthma and sinus symptoms. Our finding provide evidence that dupilumab improves overall quality of life in patients with AERD and has long-term sustained benefits. Read more here.